Eosinophilic Esophagitis - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 57 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Eosinophilic Esophagitis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Eosinophilic Esophagitis - Pipeline Review, H2 2014', provides an overview of the Eosinophilic Esophagitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Eosinophilic Esophagitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Eosinophilic Esophagitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Eosinophilic Esophagitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Eosinophilic Esophagitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Eosinophilic Esophagitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Eosinophilic Esophagitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Eosinophilic Esophagitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Eosinophilic Esophagitis Overview 7
Therapeutics Development 8
Pipeline Products for Eosinophilic Esophagitis - Overview 8
Pipeline Products for Eosinophilic Esophagitis - Comparative Analysis 9
Eosinophilic Esophagitis - Therapeutics under Development by Companies 10
Eosinophilic Esophagitis - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Eosinophilic Esophagitis - Products under Development by Companies 14
Eosinophilic Esophagitis - Companies Involved in Therapeutics Development 15
Actavis plc 15
Novartis AG 16
Teva Pharmaceutical Industries Limited 17
DBV Technologies SA 18
Meritage Pharma, Inc. 19
Oxagen Limited 20
Dr. Falk Pharma GmbH 21
Receptos, Inc. 22
Lipella Pharmaceuticals, Inc. 23
Eosinophilic Esophagitis - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
reslizumab - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
budesonide - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
OC-459 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
budesonide - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
QAX-576 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
RPC-4046 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
EUR-1100 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Drug for Eosinophilic Esophagitis - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
tacrolimus liposomal - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Eosinophilic Esophagitis - Recent Pipeline Updates 46
Eosinophilic Esophagitis - Dormant Projects 50
Eosinophilic Esophagitis - Product Development Milestones 51
Featured News & Press Releases 51
Jul 21, 2014: High-dose fluticasone effective against eosinophilic esophagitis 51
May 13, 2014: DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children 51
Aug 13, 2012: Meritage Initiates Clinical Trial Of Oral Budesonide Suspension For Adolescent And Adult Patients With Eosinophilic Esophagitis 52
May 10, 2011: Meritage Pharma Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 52
May 10, 2011: Meritage Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 54
Nov 23, 2009: Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 57
Disclaimer 57

List of Tables
Number of Products under Development for Eosinophilic Esophagitis, H2 2014 8
Number of Products under Development for Eosinophilic Esophagitis - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Eosinophilic Esophagitis - Pipeline by Actavis plc, H2 2014 15
Eosinophilic Esophagitis - Pipeline by Novartis AG, H2 2014 16
Eosinophilic Esophagitis - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 17
Eosinophilic Esophagitis - Pipeline by DBV Technologies SA, H2 2014 18
Eosinophilic Esophagitis - Pipeline by Meritage Pharma, Inc., H2 2014 19
Eosinophilic Esophagitis - Pipeline by Oxagen Limited, H2 2014 20
Eosinophilic Esophagitis - Pipeline by Dr. Falk Pharma GmbH, H2 2014 21
Eosinophilic Esophagitis - Pipeline by Receptos, Inc., H2 2014 22
Eosinophilic Esophagitis - Pipeline by Lipella Pharmaceuticals, Inc., H2 2014 23
Assessment by Monotherapy Products, H2 2014 24
Number of Products by Stage and Target, H2 2014 26
Number of Products by Stage and Mechanism of Action, H2 2014 28
Number of Products by Stage and Route of Administration, H2 2014 30
Number of Products by Stage and Molecule Type, H2 2014 32
Eosinophilic Esophagitis Therapeutics - Recent Pipeline Updates, H2 2014 46
Eosinophilic Esophagitis - Dormant Projects, H2 2014 50